WHEREAS, Aperiomics, a Sterling-based biotechnology company, has worked tirelessly in its efforts to respond to the COVID-19 pandemic; and

WHEREAS, Aperiomics combines the latest advancements in science, technology, and medicine to change the way health care providers identify causes of infection; and

WHEREAS, Aperiomics maintains a database of nearly 40,000 known pathogens, allowing precise detection of pathogens with 97 percent sensitivity and 99.99 percent specificity; and

WHEREAS, Aperiomics has helped thousands of patients and doctors recognize and treat difficult-to-diagnose infectious diseases; and

WHEREAS, Aperiomics has responded to the COVID-19 crisis by launching efforts designed to increase testing capacity in Virginia and beyond; and

WHEREAS, Aperiomics offers a suite of COVID-19 tools, including tests for the presence of the virus and for antibodies, giving patients, caregivers, and public health officials a complete picture of the virus; and

WHEREAS, Aperiomics is one of many small-to-medium-sized labs that must be a part of a state and national response to COVID-19, allowing the Commonwealth to test broadly and resume social and economic activity with confidence; and

WHEREAS, Aperiomics is coordinating with private and public health systems, local municipalities, and the Commonwealth to make as many COVID-19 tests available as possible; now, therefore, be it

RESOLVED by the House of Delegates, That Aperiomics, an esteemed biotechnology firm in Sterling, hereby be commended for its response to the challenges of the COVID-19 pandemic; and, be it

RESOLVED FURTHER, That the Clerk of the House of Delegates prepare a copy of this resolution for presentation to Aperiomics as an expression of the House of Delegates' admiration for the company's contributions to the Commonwealth during this historic public health crisis.